An AllTrials project

NCT04377659: A reported trial by Memorial Sloan Kettering Cancer Center

This trial has reported on time, in line with the regulations.

Full data

Full entry on NCT04377659
Title A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection
Results Status Reported
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date May 1, 2020
Completion date Oct. 28, 2022
Required reporting date Oct. 28, 2023, midnight
Actual reporting date May 9, 2023
Date last checked at Feb. 9, 2024
Days late None